All In Biotech

Drug Trial Radar · NCT07247188

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Jan 7, 2027

Study completion Jan 7, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

Conditions

  • Sickle Cell Disease

Interventions

  • PCV21Biological

    Investigational pneumococcal conjugate vaccine

  • 20vPCVBiological

    20-valent pneumococcal conjugate vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants reporting immediate adverse events (AEs)Time frame: Within 30 minutes post-vaccination
  2. Number of participants reporting solicited injection site and solicited systemic reactionsTime frame: Up to Day 7 post-vaccination
  3. Number of participants reporting unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs after injection of a pneumococcal vaccineTime frame: Within 30 days post-vaccination
  4. Number of participants reporting serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From day 0 to day 181
  5. Number of participants with serotype-specific immunoglobulin G (IgG) concentrations for all serotypes included in PCV21Time frame: On day 30 post-vaccination

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Site # 8400006

    Atlanta, Georgia · Recruiting

  • Site # 8400002

    Atlanta, Georgia · Recruiting

  • Site # 8400003

    Omaha, Nebraska · Recruiting

  • Site # 8400001

    New Brunswick, New Jersey · Recruiting

  • Site # 8400004

    Houston, Texas · Recruiting

  • Site # 2140001

    Santo Domingo, Dominican Republic · Recruiting

  • Site # 2140003

    Santo Domingo, Dominican Republic · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.